找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: HCV: The Journey from Discovery to a Cure; Volume II Michael J. Sofia Book 2019 Springer Nature Switzerland AG 2019 NS5B Inhibitors.NS4B In

[復(fù)制鏈接]
查看: 54956|回復(fù): 56
樓主
發(fā)表于 2025-3-21 16:16:58 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書目名稱HCV: The Journey from Discovery to a Cure
副標(biāo)題Volume II
編輯Michael J. Sofia
視頻videohttp://file.papertrans.cn/421/420174/420174.mp4
概述Provides a comprehensive compilation of discoveries that led to the cure for HCV by the leading researchers in the field.Traces all aspects of HCV research that contributed to the development of key d
叢書名稱Topics in Medicinal Chemistry
圖書封面Titlebook: HCV: The Journey from Discovery to a Cure; Volume II Michael J. Sofia Book 2019 Springer Nature Switzerland AG 2019 NS5B Inhibitors.NS4B In
描述.?Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide..This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is
出版日期Book 2019
關(guān)鍵詞NS5B Inhibitors; NS4B Inhibitors; HCV Combination Therapy; DAA therapies; Pharmacoeconimics; HCV Clinical
版次1
doihttps://doi.org/10.1007/978-3-030-28400-8
isbn_softcover978-3-030-28402-2
isbn_ebook978-3-030-28400-8Series ISSN 1862-2461 Series E-ISSN 1862-247X
issn_series 1862-2461
copyrightSpringer Nature Switzerland AG 2019
The information of publication is updating

書目名稱HCV: The Journey from Discovery to a Cure影響因子(影響力)




書目名稱HCV: The Journey from Discovery to a Cure影響因子(影響力)學(xué)科排名




書目名稱HCV: The Journey from Discovery to a Cure網(wǎng)絡(luò)公開度




書目名稱HCV: The Journey from Discovery to a Cure網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱HCV: The Journey from Discovery to a Cure被引頻次




書目名稱HCV: The Journey from Discovery to a Cure被引頻次學(xué)科排名




書目名稱HCV: The Journey from Discovery to a Cure年度引用




書目名稱HCV: The Journey from Discovery to a Cure年度引用學(xué)科排名




書目名稱HCV: The Journey from Discovery to a Cure讀者反饋




書目名稱HCV: The Journey from Discovery to a Cure讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 23:49:31 | 只看該作者
板凳
發(fā)表于 2025-3-22 00:47:29 | 只看該作者
地板
發(fā)表于 2025-3-22 04:37:11 | 只看該作者
978-3-030-28402-2Springer Nature Switzerland AG 2019
5#
發(fā)表于 2025-3-22 09:55:47 | 只看該作者
HCV: The Journey from Discovery to a Cure978-3-030-28400-8Series ISSN 1862-2461 Series E-ISSN 1862-247X
6#
發(fā)表于 2025-3-22 15:41:27 | 只看該作者
Book 2019he major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting a
7#
發(fā)表于 2025-3-22 17:46:17 | 只看該作者
8#
發(fā)表于 2025-3-22 22:40:51 | 只看該作者
9#
發(fā)表于 2025-3-23 03:31:47 | 只看該作者
10#
發(fā)表于 2025-3-23 07:25:47 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-6 16:44
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
翼城县| 教育| 呈贡县| 新泰市| 台南市| 资源县| 特克斯县| 措勤县| 崇左市| 巴林右旗| 洛南县| 获嘉县| 临沧市| 中超| 钟祥市| 贡觉县| 和顺县| 桐梓县| 宁明县| 静宁县| 东光县| 始兴县| 中方县| 阿坝县| 思茅市| 揭东县| 德惠市| 平潭县| 公安县| 徐州市| 保靖县| 三台县| 通州区| 潞西市| 石楼县| 堆龙德庆县| 九江县| 武义县| 喀什市| 桂平市| 互助|